Glomerular Disease in Temporal Association with SARS-CoV-2 Vaccination: A Series of 29 Cases

Kidney360. 2021 Sep 16;2(11):1770-1780. doi: 10.34067/KID.0005372021. eCollection 2021 Nov 25.

Abstract

Background: Immune responses to vaccination are a known trigger for a new onset of glomerular disease or disease flare in susceptible individuals. Mass immunization against SARS-CoV-2 in the COVID-19 pandemic provides a unique opportunity to study vaccination-associated autoimmune kidney diseases. In the recent literature, there are several patient reports demonstrating a temporal association of SARS-CoV-2 immunization and kidney diseases.

Methods: Here, we present a series of 29 cases of biopsy-proven glomerular disease in patients recently vaccinated against SARS-CoV-2 and identified patients who developed a new onset of IgA nephropathy, minimal change disease, membranous nephropathy, ANCA-associated GN, collapsing glomerulopathy, or diffuse lupus nephritis diagnosed on kidney biopsies postimmunization, as well as recurrent ANCA-associated GN. This included 28 cases of de novo GN within native kidney biopsies and one disease flare in an allograft.

Results: The patients with collapsing glomerulopathy were of Black descent and had two APOL1 genomic risk alleles. A brief literature review of patient reports and small series is also provided to include all reported cases to date (n=52). The incidence of induction of glomerular disease in response to SARS-CoV-2 immunization is unknown; however, there was no overall increase in incidence of glomerular disease when compared with the 2 years prior to the COVID-19 pandemic diagnosed on kidney biopsies in our practice.

Conclusions: Glomerular disease to vaccination is rare, although it should be monitored as a potential adverse event.

Keywords: ANCA; APOL1; COVID-19; IgA nephropathy; SARS-CoV-2 vaccine; collapsing glomerulopathy; crescentic glomerulonephritis; glomerular and tubulointerstitial diseases; lupus nephritis; membranous nephropathy; minimal change disease.

MeSH terms

  • Apolipoprotein L1
  • COVID-19 Vaccines / adverse effects
  • COVID-19*
  • Glomerulonephritis, IGA* / epidemiology
  • Humans
  • Pandemics
  • SARS-CoV-2
  • Vaccination / adverse effects

Substances

  • APOL1 protein, human
  • Apolipoprotein L1
  • COVID-19 Vaccines